vs
FOSTER L B CO（FSTR）与VERACYTE, INC.（VCYT）财务数据对比。点击上方公司名可切换其他公司
FOSTER L B CO的季度营收约是VERACYTE, INC.的1.2倍（$160.4M vs $139.1M），VERACYTE, INC.净利率更高（20.6% vs 1.5%，领先19.1%），FOSTER L B CO同比增速更快（25.1% vs 21.5%），过去两年FOSTER L B CO的营收复合增速更高（13.6% vs 10.2%）
Foster L B Co.是一家总部位于美国的专业工业制造企业，主要生产销售工程通道产品、建筑组件及铁路基础设施用品，服务覆盖北美及部分全球地区的商业建筑、交通和工业领域客户。
Veracyte是一家领先的分子诊断企业，专注开发专有的基因组检测方案，可实现癌症及其他复杂疾病的早期精准检测，产品服务于医疗机构以优化临床决策，核心市场位于美国，正稳步拓展全球业务布局。
FSTR vs VCYT — 直观对比
营收规模更大
FSTR
是对方的1.2倍
$139.1M
营收增速更快
FSTR
高出3.6%
21.5%
净利率更高
VCYT
高出19.1%
1.5%
两年增速更快
FSTR
近两年复合增速
10.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $160.4M | $139.1M |
| 净利润 | $2.4M | $28.7M |
| 毛利率 | 19.7% | 72.7% |
| 营业利润率 | 4.9% | 16.3% |
| 净利率 | 1.5% | 20.6% |
| 营收同比 | 25.1% | 21.5% |
| 净利润同比 | 1098.3% | — |
| 每股收益（稀释后） | $0.22 | $0.35 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FSTRVCYT
| Q1 26 | — | $139.1M | ||
| Q4 25 | $160.4M | $140.6M | ||
| Q3 25 | $138.3M | $131.9M | ||
| Q2 25 | $143.6M | $130.2M | ||
| Q1 25 | $97.8M | $114.5M | ||
| Q4 24 | $128.2M | $118.6M | ||
| Q3 24 | $137.5M | $115.9M | ||
| Q2 24 | $140.8M | $114.4M |
净利润FSTRVCYT
| Q1 26 | — | $28.7M | ||
| Q4 25 | $2.4M | $41.1M | ||
| Q3 25 | $4.4M | $19.1M | ||
| Q2 25 | $2.9M | $-980.0K | ||
| Q1 25 | $-2.1M | $7.0M | ||
| Q4 24 | $-242.0K | $5.1M | ||
| Q3 24 | $35.9M | $15.2M | ||
| Q2 24 | $2.8M | $5.7M |
毛利率FSTRVCYT
| Q1 26 | — | 72.7% | ||
| Q4 25 | 19.7% | 72.5% | ||
| Q3 25 | 22.5% | 69.2% | ||
| Q2 25 | 21.5% | 69.0% | ||
| Q1 25 | 20.6% | 69.5% | ||
| Q4 24 | 22.3% | 66.4% | ||
| Q3 24 | 23.8% | 68.2% | ||
| Q2 24 | 21.7% | 68.1% |
营业利润率FSTRVCYT
| Q1 26 | — | 16.3% | ||
| Q4 25 | 4.9% | 26.4% | ||
| Q3 25 | 6.0% | 17.4% | ||
| Q2 25 | 5.3% | -4.0% | ||
| Q1 25 | -2.0% | 2.5% | ||
| Q4 24 | 2.4% | 3.5% | ||
| Q3 24 | 5.3% | 10.4% | ||
| Q2 24 | 3.2% | 4.0% |
净利率FSTRVCYT
| Q1 26 | — | 20.6% | ||
| Q4 25 | 1.5% | 29.3% | ||
| Q3 25 | 3.1% | 14.5% | ||
| Q2 25 | 2.0% | -0.8% | ||
| Q1 25 | -2.2% | 6.2% | ||
| Q4 24 | -0.2% | 4.3% | ||
| Q3 24 | 26.1% | 13.1% | ||
| Q2 24 | 2.0% | 5.0% |
每股收益（稀释后）FSTRVCYT
| Q1 26 | — | $0.35 | ||
| Q4 25 | $0.22 | $0.50 | ||
| Q3 25 | $0.40 | $0.24 | ||
| Q2 25 | $0.27 | $-0.01 | ||
| Q1 25 | $-0.20 | $0.09 | ||
| Q4 24 | $-0.04 | $0.07 | ||
| Q3 24 | $3.27 | $0.19 | ||
| Q2 24 | $0.26 | $0.07 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.3M | $439.1M |
| 总债务越低越好 | $42.6M | — |
| 股东权益账面价值 | $175.3M | $1.3B |
| 总资产 | $330.4M | $1.4B |
| 负债/权益比越低杠杆越低 | 0.24× | — |
8季度趋势，按日历期对齐
现金及短期投资FSTRVCYT
| Q1 26 | — | $439.1M | ||
| Q4 25 | $4.3M | $362.6M | ||
| Q3 25 | $3.4M | $315.6M | ||
| Q2 25 | $4.2M | $219.5M | ||
| Q1 25 | $2.6M | $186.1M | ||
| Q4 24 | $2.5M | $239.1M | ||
| Q3 24 | $3.1M | $274.1M | ||
| Q2 24 | $4.0M | $235.9M |
总债务FSTRVCYT
| Q1 26 | — | — | ||
| Q4 25 | $42.6M | — | ||
| Q3 25 | $58.6M | — | ||
| Q2 25 | $81.4M | — | ||
| Q1 25 | $82.3M | — | ||
| Q4 24 | $46.8M | — | ||
| Q3 24 | $68.4M | — | ||
| Q2 24 | $87.0M | — |
股东权益FSTRVCYT
| Q1 26 | — | $1.3B | ||
| Q4 25 | $175.3M | $1.3B | ||
| Q3 25 | $174.8M | $1.3B | ||
| Q2 25 | $174.4M | $1.2B | ||
| Q1 25 | $170.8M | $1.2B | ||
| Q4 24 | $178.3M | $1.2B | ||
| Q3 24 | $181.9M | $1.2B | ||
| Q2 24 | $147.1M | $1.1B |
总资产FSTRVCYT
| Q1 26 | — | $1.4B | ||
| Q4 25 | $330.4M | $1.4B | ||
| Q3 25 | $333.9M | $1.4B | ||
| Q2 25 | $349.9M | $1.3B | ||
| Q1 25 | $342.8M | $1.3B | ||
| Q4 24 | $334.6M | $1.3B | ||
| Q3 24 | $344.5M | $1.3B | ||
| Q2 24 | $333.3M | $1.2B |
负债/权益比FSTRVCYT
| Q1 26 | — | — | ||
| Q4 25 | 0.24× | — | ||
| Q3 25 | 0.33× | — | ||
| Q2 25 | 0.47× | — | ||
| Q1 25 | 0.48× | — | ||
| Q4 24 | 0.26× | — | ||
| Q3 24 | 0.38× | — | ||
| Q2 24 | 0.59× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $22.2M | $35.2M |
| 自由现金流经营现金流 - 资本支出 | $19.8M | — |
| 自由现金流率自由现金流/营收 | 12.3% | — |
| 资本支出强度资本支出/营收 | 1.5% | — |
| 现金转化率经营现金流/净利润 | 9.18× | 1.23× |
| 过去12个月自由现金流最近4个季度 | $25.2M | — |
8季度趋势，按日历期对齐
经营现金流FSTRVCYT
| Q1 26 | — | $35.2M | ||
| Q4 25 | $22.2M | $52.6M | ||
| Q3 25 | $29.2M | $44.8M | ||
| Q2 25 | $10.4M | $33.6M | ||
| Q1 25 | $-26.1M | $5.4M | ||
| Q4 24 | $24.3M | $24.5M | ||
| Q3 24 | $24.7M | $30.0M | ||
| Q2 24 | $-5.0M | $29.6M |
自由现金流FSTRVCYT
| Q1 26 | — | — | ||
| Q4 25 | $19.8M | $48.8M | ||
| Q3 25 | $26.4M | $42.0M | ||
| Q2 25 | $7.7M | $32.3M | ||
| Q1 25 | $-28.7M | $3.5M | ||
| Q4 24 | $22.3M | $20.4M | ||
| Q3 24 | $21.7M | $27.7M | ||
| Q2 24 | $-7.0M | $26.8M |
自由现金流率FSTRVCYT
| Q1 26 | — | — | ||
| Q4 25 | 12.3% | 34.7% | ||
| Q3 25 | 19.1% | 31.8% | ||
| Q2 25 | 5.4% | 24.8% | ||
| Q1 25 | -29.4% | 3.1% | ||
| Q4 24 | 17.4% | 17.2% | ||
| Q3 24 | 15.8% | 23.9% | ||
| Q2 24 | -5.0% | 23.4% |
资本支出强度FSTRVCYT
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 2.7% | ||
| Q3 25 | 2.0% | 2.1% | ||
| Q2 25 | 1.9% | 1.0% | ||
| Q1 25 | 2.6% | 1.6% | ||
| Q4 24 | 1.5% | 3.5% | ||
| Q3 24 | 2.2% | 1.9% | ||
| Q2 24 | 1.5% | 2.4% |
现金转化率FSTRVCYT
| Q1 26 | — | 1.23× | ||
| Q4 25 | 9.18× | 1.28× | ||
| Q3 25 | 6.70× | 2.34× | ||
| Q2 25 | 3.61× | — | ||
| Q1 25 | — | 0.76× | ||
| Q4 24 | — | 4.80× | ||
| Q3 24 | 0.69× | 1.98× | ||
| Q2 24 | -1.74× | 5.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FSTR
| Rail Technologies And Services Segment | $98.0M | 61% |
| Over Time Output Method | $26.3M | 16% |
| Services | $19.4M | 12% |
| Rail Technologies Products | $10.0M | 6% |
| Over Time Input Method | $8.3M | 5% |
VCYT
| Testing revenue | $135.1M | 97% |
| Product revenue | $3.7M | 3% |
| Biopharmaceutical and other revenue | $301.0K | 0% |
